Please use this identifier to cite or link to this item:
Author(s): Araújo, N
Costa, A
Lopes-Conceição, L
Ferreira, A
Carneiro, F
Oliveira, J
Braga, I
Morais, S
Pacheco-Figueiredo, L
Ruano, L
Cruz, VT
Pereira, S
Lunet, N
Title: Androgen-deprivation therapy and cognitive decline in the NEON-PC prospective study during the COVID-19 pandemic
Publisher: Elsevier
Issue Date: 2022
Abstract: Background: Androgen-deprivation therapy (ADT) has been associated with cognitive decline, but results are conflicting. This study describes changes in cognitive performance in patients with prostate cancer, according to ADT, during the first year after prostate cancer diagnosis. Patients and methods: Patients with prostate cancer treated at the Portuguese Institute of Oncology of Porto (n = 366) were evaluated with the Montreal Cognitive Assessment (MoCA), before treatment and after 1 year. All baseline evaluations were performed before the coronavirus disease 2019 (COVID-19) pandemic and 69.7% of the 1-year assessments were completed after the first lockdown. Cognitive decline was defined as the decrease in MoCA from baseline to the 1-year evaluation below 1.5 standard deviations of the distribution of changes in the whole cohort. Participants scoring below age- and education-specific normative reference values in the MoCA were considered to have cognitive impairment. Age- and education-adjusted odds ratios (aORs) were computed for the association between ADT and cognitive outcomes. Results: Mean MoCA scores increased from baseline to the 1-year evaluation (22.3 versus 22.8, P < 0.001). Cognitive decline was more frequent in the ADT group, and even more after the onset of the COVID-19 pandemic (aOR 6.81 versus 1.93, P for interaction = 0.233). The 1-year cumulative incidence of cognitive impairment was 6.9% (9.1% before and 3.7% after the pandemic onset), which was higher among patients receiving ADT, but only after the pandemic (aOR 5.53 versus 0.49, P for interaction = 0.044). Conclusions: ADT was associated with worse cognitive performance of patients with prostate cancer, mostly among those evaluated after the first COVID-19 lockdown. © 2022 The Authors
Subject: COVID-19, complications; hormone antagonists/analogues and derivatives; hormone substitutes; hormones; longitudinal studies; neurocognitive disorders; prostate cancer
Source: ESMO Open. 2022 Apr;7(2):100448. doi: 10.1016/j.esmoop.2022.100448. Epub 2022 Mar 7.
Related Information: info:eu-repo/grantAgreement/FCT/9471 - RIDTI/PTDC/SAU-EPI/32358/2017/PT
info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB/04750/2020/PT
info:eu-repo/grantAgreement/FCT/9471 - RIDTI/PTDC/SAU-EPI/32358/2017/PT
Document Type: Artigo em Revista Científica Internacional
Rights: openAccess
Appears in Collections:ISPUP - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
araujo-esmoo-2022.pdf390.42 kBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons